Last updated on April 18, 2014 at 14:49 EDT

Positive Clinical Study Results, New Product Launches, and Leadership Changes – Research Report on Allergan, Isis, Covidien, BD, and DaVita HealthCare Partners

June 27, 2013

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, June 27, 2013 /PRNewswire/ –

Today, Wall Street Reports announced new research reports highlighting Allergan, Inc.
(NYSE: AGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Covidien plc (NYSE: COV), Becton,
Dickinson and Co. (NYSE: BDX) and DaVita Healthcare Partners Inc. (NYSE: DVA). Today’s
readers may access these reports free of charge – including full price targets, industry
analysis and analyst ratings – via the links below.

Allergan, Inc. Research Report

On June 24, 2013, Allergan, Inc. (Allergan) announced that David E.I. Pyott, Chairman
of the Board and Chief Executive Officer of Allergan, and the Company’s Board of
Directors, have named Douglas S. Ingram as President of Allergan. Ingram will lead
Allergan’s global commercial operations, with responsibility for the Company’s broad
portfolio of pharmaceutical, consumer, and medical device products, including its leading
OZURDEX), facial aesthetics products (e.g. BOTOX and JUVEDERM), and medical dermatology
products (e.g. ACZONE). Allergan stated that Ingram has been with the Company for 17
years, and for the past three years, Ingram has served as the Company’s Executive Vice
President and President, Europe, Africa and Middle East (EAME), where he was responsible
for Allergan’s regional pharmaceutical and medical device operations, with a focus on
strategic planning, sales and marketing, development and general management. Full Research
Report on Allergan, Inc. – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at: [


ISIS Pharmaceuticals, Inc. Research Report

On June 23, 2013, ISIS Pharmaceuticals Inc. (Isis) announced data from Phase 2 study
of ISIS-APOCIII in patients with high triglycerides and type 2 diabetes. In the study,
patients treated with ISIS-APOCIII experienced an 88% reduction in apolipoprotein C-III
(apoC-III), a 72% reduction in triglyceride levels, a 40% increase in high-density
lipoprotein cholesterol (HDL-C), the ‘good’ cholesterol, and improvements in other
atherogenic lipid parameters. Further, patients dosed with ISIS-APOCIIIRx showed
consistent trends towards enhanced insulin sensitivity with improvements in multiple
measures of glucose control. The Company also stated that it is evaluating ISIS-APOCIII in
a separate Phase 2 study in patients with moderate to high triglycerides and expects to
report data from the study in the summer of 2013. The Full Research Report on ISIS
Pharmaceuticals, Inc. – including full detailed breakdown, analyst ratings and price
targets – is available to download free of charge at: [


Covidien plc Research Report

On June 20, 2013, Covidien plc (Covidien) announced that an independent study called
CLOTS 3, conducted by the University of Edinburgh, successfully demonstrated the
effectiveness of Covidien’s Kendall SCD system with Vascular Refill Detection Technology
on immobile stroke patients. The study showed a 29.9% decrease in the development of
proximal deep vein thrombosis (DVP) in immobile stroke patients who received intermittent
pneumatic compression (IPC) using the Kendall SCD system with Vascular Refill Detection
Technology, which as per the Company, delivers sequential, circumferential, gradient
compression through thigh-length sleeves. Compared to the routine care group, the IPC
group showed a 14% mortality risk reduction (p = 0.042) during the first six months after
admission for stroke. The results of the CLOTS 3 trial were presented at the European
Stroke Conference and were also published in the medical journal, The Lancet. The Full
Research Report on Covidien plc – including full detailed breakdown, analyst ratings and
price targets – is available to download free of charge at: [


Becton, Dickinson and Co. Research Report

On June 24, 2013, BD Diagnostics, a segment of Becton, Dickinson and Co. (BD),
together with Diagenode SA, an international biotech company based in Belgium, announced
the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time
polymerase chain reaction (PCR) kit for use on the BD MAX System. According to the
Company, Bordetella pertussis is responsible for 30-50 million annual cases of pertussis,
or the “whooping cough.” Timely detection of the infection through the PCR is essential in
preventing the spread of disease and reducing the risk of widespread outbreaks. BD further
stated that PCR testing is ideal in enabling the prompt differential diagnosis of
pertussis from other respiratory diseases such as atypical pneumonia, bronchitis, or
respiratory viruses. Through BD’s collaborations with leading in vitro diagnostic (IVD)
developers such as Diagenode, the Company is rapidly expanding its molecular testing menu
by offering syndrome specific and clinically relevant IVD assays across a number of
disease syndromes. The Full Research Report on Becton, Dickinson and Co. – including full
detailed breakdown, analyst ratings and price targets – is available to download free of
charge at: [http://www.wsreports.com/r/full_research_report/0978_BDX]

DaVita Healthcare Partners Inc. Research Report

On June 24, 2013, DaVita, the dialysis division of DaVita HealthCare Partners Inc.
(DaVita HealthCare Partners), announced that it has selected Cureatr, the enterprise
messaging and workflow navigation solution for healthcare, to enhance communication and
care coordination for care teams at dialysis centers across the country. The Company said
that Cureatr’s mobile care coordination and reporting system will enable DaVita foster
more robust clinical information sharing, which may help reduce costly hospital
admissions. Also, it stated that this partnership allows DaVita to provide Cureatr’s
iPhone and web apps to thousands of facility administrators, care managers, nurses, and
affiliated nephrologists. The Company also expects this to improve communication between
DaVita’s dialysis care teams, resulting in more efficient delivery of patient care.The
Full Research Report on DaVita Healthcare Partners Inc. – including full detailed
breakdown, analyst ratings and price targets – is available to download free of charge at:


        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
        5) For any urgent concerns or inquiries, please contact us at
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for


Content is researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Equity News Network. An outsourced research
services provider has, through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according to the Procedures
outlined by Equity News Network. Equity News Network is not entitled to veto or interfere
in the application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No liability is
accepted by Equity News Network whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Equity News Network expressly disclaims any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Equity News Network does not
(1) guarantee the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The included
information is subject to change without notice.

SOURCE Wall Street Reports

Source: PR Newswire